# DEA Admits Teen Cannabis Use Has Drastically Decreased Since 1995, Despite Dozens of … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-admits-legal-cannabis-isnt-increasing-youth-use/ > **Published:** 2026-03-18T21:13:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:08-04:00 > **Clinical Summary:** DEA admits legal cannabis isn't increasing youth use, showing adolescent cannabis use has declined since 1995 despite legalization. --- ✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchPediatricsSafety Clinical Summary A recent DEA acknowledgment reveals that past-year cannabis use among adolescents and teens has declined substantially from 1995 to 2025, contrary to widespread public concerns about increasing youth substance use. This finding is significant for clinicians because it challenges the narrative that [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and increased availability have necessarily led to higher adolescent consumption rates, and suggests that other factors including education, prevention programs, and changing social norms may be effectively reducing youth initiation and regular use. The data provides evidence that regulatory approaches to cannabis, when paired with public health messaging, may not automatically increase youth access or use despite greater adult availability in legalized jurisdictions. Understanding this trend helps contextualize clinical discussions with parents and adolescent patients about cannabis risks, as the actual epidemiology differs from perception-based fears that often shape patient concerns and decision-making. Clinicians can use this evidence to engage in more precise risk communication with families while continuing to emphasize evidence-based harms specific to developing brains without overstating population-level trends. The practical takeaway is that clinicians should reference actual prevalence data rather than assumed increases when counseling families about adolescent cannabis use, allowing for more credible and effective prevention conversations. Dr. Caplan’s Take “What this data tells us is that the prohibition messaging of the 1980s and 90s has actually worked on the demographic we were most concerned about, which means we can now have a more honest conversation with patients and parents about cannabis based on actual risk stratification rather than categorical fear. The science supports what we’re seeing: when we treat this as a medical question instead of a moral one, teenagers make more rational choices, and those of us in clinical practice can finally focus on the real vulnerabilities, like early use in kids with genetic predisposition to psychosis or those with developing brains, rather than pretending all use carries equal risk.” Clinical Perspective The documented decline in adolescent cannabis use since 1995, despite legalization in many jurisdictions, presents an important corrective to widespread assumptions about cannabis policy and youth behavior. This trend likely reflects multiple confounding factors including evolving social norms, improved prevention messaging, increased awareness of developmental neurotoxicity, and potentially counterintuitive effects of regulated markets that may reduce youth access compared to illicit alternatives. However, clinicians should remain cautious, as recent data also show concerning patterns of increased potency in available products, shifting routes of consumption (particularly edibles and concentrates), and potential disparities in use and consequences across socioeconomic and racial groups that warrant closer examination. The apparent overall decline does not negate the significant risks of cannabis exposure during critical periods of brain development, particularly for vulnerable youth including those with psychiatric predisposition or substance use vulnerability. Clinicians should continue routine screening for cannabis use in adolescent populations, educ 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+DEA+Admits+Teen+Cannabis+Use+Has+Drastically+Decreased+Since+1995%2C+Despite+Dozens+of+...+%40drcaplan&url=https%3A%2F%2Fthemarijuanaherald.com%2F2026%2F03%2Fdea-admits-teen-cannabis-use%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fthemarijuanaherald.com%2F2026%2F03%2Fdea-admits-teen-cannabis-use%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+DEA+Admits+Teen+Cannabis+Use+Has+Drastically+Decreased+Since+1995%2C+Despite+Dozens+of+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fthemarijuanaherald.com%2F2026%2F03%2Fdea-admits-teen-cannabis-use%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://themarijuanaherald.com/2026/03/dea-admits-teen-cannabis-use/](https://themarijuanaherald.com/2026/03/dea-admits-teen-cannabis-use/) Further Reading Research Digest[PM News Update: March 17, 2026](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/) CED Clinic Blog[A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.](https://cedclinic.com/cannabidiol-effects-on-appetite/) Cannabis Policy Wire[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://cedclinic.com/scheduling-novel-synthetic-opioids-schedule-i/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DEA admits legal cannabis isn't increasing youth use (Newsletter: March 19, 2026)](https://cedclinic.com/legal-cannabis-youth-use-data-no-increase/) Explore the DEA's recent acknowledgment that legal cannabis has not led to increased youth consumption, providing important context for clinicians and policymakers. [Read More](https://cedclinic.com/legal-cannabis-youth-use-data-no-increase/) Teen Cannabis Use Mirrors Alcohol Consumption Trends – Mirage News This article compares teen cannabis use trends with alcohol consumption patterns, offering insights into adolescent substance use behaviors. Explore Article [Teen cannabis use trends mirror established alcohol consumption patterns](https://cedclinic.com/teen-cannabis-use-trends-alcohol-consumption-patterns/) A detailed look at how teen cannabis use trends align with long-standing alcohol consumption behaviors among adolescents. [Learn More](https://cedclinic.com/teen-cannabis-use-trends-alcohol-consumption-patterns/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).